DHR vs. JAZZ: Danaher vs. Jazz Pharmaceuticals Stock Comparison
How do Danaher (DHR) and Jazz Pharmaceuticals (JAZZ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Danaher (DHR) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but DHR is classified in Life Sciences Tools & Services while JAZZ is classified in Pharmaceuticals.
| Profile Item | DHR | JAZZ |
|---|---|---|
| Name | Danaher Corp. | Jazz Pharmaceuticals plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 161.86 billion USD | 15.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | December 29, 1978 | June 1, 2007 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| Total Return (1Y) | 11.88% | 84.44% |
| Total Return (3Y, Annualized) | 6.67% | 27.57% |
| Total Return (5Y, Annualized) | -2.05% | 12.88% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| Volatility (1Y, Annualized) | 30.61% | 38.74% |
| Beta (5Y) | 0.76 | 0.33 |
| Max Drawdown (5Y) | -43.31% | -42.03% |
| Avg. Volume (3M) | 3.94M | 878.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| Sharpe Ratio (1Y) | 0.25 | 2.07 |
| Sortino Ratio (1Y) | 0.35 | 4.14 |
Profitability
ROE (TTM)
Danaher (DHR) at 8.19% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for DHR.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 109.18%
- DHR
- 8.19%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Danaher (DHR) at 16.91% retains a top-quartile share of revenue as profit, ahead of Jazz Pharmaceuticals (JAZZ) at 4.37%, which keeps about the industry-typical share.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.91%
- Max
- 18.05%
- DHR
- 16.91%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Danaher (DHR) at 21.13% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.13%
- Max
- 83.12%
- DHR
- 21.13%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| ROE (TTM) | 8.19% | 5.05% |
| ROA (TTM) | 4.06% | 6.92% |
| Net Margin (TTM) | 16.91% | 4.37% |
| Operating Margin (TTM) | 21.13% | 30.17% |
| Gross Margin (TTM) | 59.36% | 91.10% |
Growth
Revenue Growth
Both Danaher (DHR) at 2.90% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Danaher (DHR) at -4.54% is around its peer norm for EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| Revenue Growth (YoY) | 2.90% | 4.88% |
| Revenue Growth (3Y CAGR) | -2.67% | 5.26% |
| EPS Growth (YoY) | -4.54% | -167.51% |
| EPS Growth (3Y CAGR) | -19.44% | -- |
Financial Strength
Current Ratio (MRQ)
Both Danaher (DHR) at 1.63 and Jazz Pharmaceuticals (JAZZ) at 1.82 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- DHR
- 1.63
- Min
- 0.10
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
Debt / Equity (MRQ)
Danaher (DHR) at 0.52 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.52
- Max
- 1.42
- Q3
- 0.65
- DHR
- 0.52
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| Current Ratio (MRQ) | 1.63 | 1.82 |
| Debt / Equity (MRQ) | 0.52 | 1.35 |
| Net Debt / EBITDA | 2.68 | 1.39 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67%
- DHR
- 0.67%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.17%
- DHR
- 25.17%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| Dividend Yield (TTM) | 0.67% | 0.00% |
| Dividend Payout Ratio (TTM) | 25.17% | 0.00% |
Valuation
P/E Ratio (TTM)
Danaher (DHR) at 38.12 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.12
- Max
- 85.34
- Q3
- 43.46
- DHR
- 38.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Danaher (DHR) at 6.32 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.32
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- DHR
- 6.32
- Q1
- 3.01
- Min
- 0.01
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Danaher (DHR) at 3.02 and Jazz Pharmaceuticals (JAZZ) at 3.59 are valued close to their industries’ norm against book — neither stands out from peers.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- DHR
- 3.02
- Q1
- 1.69
- Min
- -5.59
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | DHR | JAZZ |
|---|---|---|
| P/E Ratio (TTM) | 38.12 | 69.46 |
| P/S Ratio (TTM) | 6.32 | 3.19 |
| P/B Ratio (MRQ) | 3.02 | 3.59 |
| Free Cash Flow Yield (TTM) | 2.93% | 11.16% |